Olita (olmutinib) / Hanmi  >>  Phase 1
Welcome,         Profile    Billing    Logout  

3 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Olita (olmutinib) / Hanmi
NCT04510415: Olmutinib 600 mg QD in Patients With T790M-positive NSCLC After Treatment With an EGFR-TKI

Terminated
1b
2
RoW
Olmutinib, HM61713
Hanmi Pharmaceutical Company Limited
Non Small Cell Lung Cancer
12/18
12/18
NCT01894399: Study to Evaluate a Pharmacokinetic of HM61713 in Healthy Male Subjects

Completed
1
59
RoW
HM61713, Olmutinib
Hanmi Pharmaceutical Company Limited
Healthy Volunteers
11/13
11/13
NCT02722161: Olmutinib (BI 1482694) ADME Study

Completed
1
8
Europe
[14C]BI 1482694
Boehringer Ingelheim
Healthy
06/16
06/16

Download Options